Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Vertex Pharmaceuticals (VRTX) wrapped up July with a modest 0.16% uptick, signaling a cautious optimism in the stock market.

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in ...